Glycans and glycoproteins as specific biomarkers for cancer

Muchena J. Kailemia, Dayoung Park, Carlito B Lebrilla

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Protein glycosylation and other post-translational modifications are involved in potentially all aspects of human growth and development. Defective glycosylation has adverse effects on human physiological conditions and accompanies many chronic and infectious diseases. Altered glycosylation can occur at the onset and/or during tumor progression. Identifying these changes at early disease stages may aid in making decisions regarding treatments, as early intervention can greatly enhance survival. This review highlights some of the efforts being made to identify N- and O-glycosylation profile shifts in cancer using mass spectrometry. The analysis of single or panels of potential glycoprotein cancer markers are covered. Other emerging technologies such as global glycan release and site-specific glycosylation analysis and quantitation are also discussed. [Figure not available: see fulltext.]

Original languageEnglish (US)
Pages (from-to)1-16
Number of pages16
JournalAnalytical and Bioanalytical Chemistry
DOIs
StateAccepted/In press - Sep 3 2016

Fingerprint

Glycosylation
Tumor Biomarkers
Polysaccharides
Glycoproteins
Neoplasms
Human Development
Post Translational Protein Processing
Growth and Development
Communicable Diseases
Mass spectrometry
Tumors
Mass Spectrometry
Decision Making
Chronic Disease
Decision making
Technology
Survival
Proteins

Keywords

  • Cancer
  • Disease biomarker
  • Glycomics
  • Glycoproteomics
  • Mass spectrometry
  • Site-specific glycosylation

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry

Cite this

Glycans and glycoproteins as specific biomarkers for cancer. / Kailemia, Muchena J.; Park, Dayoung; Lebrilla, Carlito B.

In: Analytical and Bioanalytical Chemistry, 03.09.2016, p. 1-16.

Research output: Contribution to journalArticle

Kailemia, Muchena J. ; Park, Dayoung ; Lebrilla, Carlito B. / Glycans and glycoproteins as specific biomarkers for cancer. In: Analytical and Bioanalytical Chemistry. 2016 ; pp. 1-16.
@article{77aa8a5269d04431acf76d0a3dec44f3,
title = "Glycans and glycoproteins as specific biomarkers for cancer",
abstract = "Protein glycosylation and other post-translational modifications are involved in potentially all aspects of human growth and development. Defective glycosylation has adverse effects on human physiological conditions and accompanies many chronic and infectious diseases. Altered glycosylation can occur at the onset and/or during tumor progression. Identifying these changes at early disease stages may aid in making decisions regarding treatments, as early intervention can greatly enhance survival. This review highlights some of the efforts being made to identify N- and O-glycosylation profile shifts in cancer using mass spectrometry. The analysis of single or panels of potential glycoprotein cancer markers are covered. Other emerging technologies such as global glycan release and site-specific glycosylation analysis and quantitation are also discussed. [Figure not available: see fulltext.]",
keywords = "Cancer, Disease biomarker, Glycomics, Glycoproteomics, Mass spectrometry, Site-specific glycosylation",
author = "Kailemia, {Muchena J.} and Dayoung Park and Lebrilla, {Carlito B}",
year = "2016",
month = "9",
day = "3",
doi = "10.1007/s00216-016-9880-6",
language = "English (US)",
pages = "1--16",
journal = "Fresenius Zeitschrift fur Analytische Chemie",
issn = "0016-1152",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Glycans and glycoproteins as specific biomarkers for cancer

AU - Kailemia, Muchena J.

AU - Park, Dayoung

AU - Lebrilla, Carlito B

PY - 2016/9/3

Y1 - 2016/9/3

N2 - Protein glycosylation and other post-translational modifications are involved in potentially all aspects of human growth and development. Defective glycosylation has adverse effects on human physiological conditions and accompanies many chronic and infectious diseases. Altered glycosylation can occur at the onset and/or during tumor progression. Identifying these changes at early disease stages may aid in making decisions regarding treatments, as early intervention can greatly enhance survival. This review highlights some of the efforts being made to identify N- and O-glycosylation profile shifts in cancer using mass spectrometry. The analysis of single or panels of potential glycoprotein cancer markers are covered. Other emerging technologies such as global glycan release and site-specific glycosylation analysis and quantitation are also discussed. [Figure not available: see fulltext.]

AB - Protein glycosylation and other post-translational modifications are involved in potentially all aspects of human growth and development. Defective glycosylation has adverse effects on human physiological conditions and accompanies many chronic and infectious diseases. Altered glycosylation can occur at the onset and/or during tumor progression. Identifying these changes at early disease stages may aid in making decisions regarding treatments, as early intervention can greatly enhance survival. This review highlights some of the efforts being made to identify N- and O-glycosylation profile shifts in cancer using mass spectrometry. The analysis of single or panels of potential glycoprotein cancer markers are covered. Other emerging technologies such as global glycan release and site-specific glycosylation analysis and quantitation are also discussed. [Figure not available: see fulltext.]

KW - Cancer

KW - Disease biomarker

KW - Glycomics

KW - Glycoproteomics

KW - Mass spectrometry

KW - Site-specific glycosylation

UR - http://www.scopus.com/inward/record.url?scp=84984918427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984918427&partnerID=8YFLogxK

U2 - 10.1007/s00216-016-9880-6

DO - 10.1007/s00216-016-9880-6

M3 - Article

C2 - 27590322

AN - SCOPUS:84984918427

SP - 1

EP - 16

JO - Fresenius Zeitschrift fur Analytische Chemie

JF - Fresenius Zeitschrift fur Analytische Chemie

SN - 0016-1152

ER -